Hospital earnings calls starting on April 23rd are not going to surprise anyone paying attention to Washington DC or to the healthcare revenue cycle management ("RCM") vendors that have been signaling warnings for weeks.

The announcements are going to confirm what deliberate policy choices made in late 2024 and 2025 set into motion. The budget negotiations, the continuing resolution standoffs, and the government shutdowns revolved around healthcare policy. What opens now is the revenue cycle reading those decisions back to the industry, in the only language that registers at scale: the numbers.

WHAT WAS DECIDED, AND WHEN

It is worth being direct about the causal chain, because earnings commentary will not. 

The political drama of last fall conspired to produce a specific and predictable set of downstream consequences. Coverage grace periods tied to those negotiations began terminating on April 1, creating retroactive coverage loss on commercial claims. Medicaid disenrollment, which had been artificially suppressed through continuous enrollment protections, is now accelerating again. ACA participation, no longer propped up by the subsidy structures that stabilized enrollment through 2023 and 2024, is churning in ways the exchanges are only beginning to register. In short, a period of broad government policy-backed benefit expansion is in a reversal phase, gaining steam in its second full year.

None of this is mysterious. These were policy choices with known actuarial consequences, made by people who understood exactly what they were choosing. What is arriving now in hospital revenue cycles is not an emerging phenomenon. It is a scheduled outcome.

A SQUEEZE FROM BOTH SIDES

If payer mix erosion were the only spoiler, the story would be manageable. Health systems have navigated coverage churn before. But what makes this moment structurally different is that it is arriving simultaneously with a separate policy force moving in the same direction: site-neutral payment reform.

The CMS policy, now advancing with increasing regulatory confidence, establishes that the same procedure be reimbursed at the same rate regardless of whether it is performed in a hospital outpatient department or an independent physician office or ambulatory surgery center. For health systems that built their outpatient strategy around facility fee capture, this is not a marginal adjustment. It is a direct challenge to a core margin assumption and erodes years of strategic acquisition.

WHAT THE EARNINGS CALLS WITH ACTUALLY TELL US

The calendar lines up almost too cleanly. CHS and HCA report first, the week of April 23rd, offering the initial read on whether the signal is already measurable or still forming beneath the surface. Tenet and UHS follow a week later, where the story either confirms something undeniable or gets softened, explained, and rationalized into something more comfortable.

Watch the language as closely as the numbers.

Outpatient softness, if it appears, will be framed as transient. Emergency volume strength will be positioned as a positive. First quarter demand softness will receive more emphasis than it would in a normal first quarter, but systems are quietly building plans to absorb what they already know is coming.

Ensemble Health Partners flagged this dynamic explicitly in recent commentary, describing two forces beginning to collide: coverage quietly eroding while affordability, even for those who nominally remain insured, begins to give way. What is notable is that they are not describing a forecast. They are describing operational Q1 data already in motion.

In our last issue we touched on the topic of Claim Intensity. The payer response was a plan design shift to higher cost share which Ensemble is also noting as a headwind in first quarter 2026.

THE LAG IS THE RISK

The most important analytical point for health system leadership is one the earnings calls are structurally unable to communicate cleanly. Policy acts fast. Health systems absorb slowly.

The coverage terminations that began April 1 will take months to fully surface in volume and acuity data. The behavioral consequences of deferred diagnostics, avoided follow-ups, delayed elective procedures, will appear early as demand softness but accumulate quietly. The patients do not disappear. They defer. And when they return, they return sicker, under worse circumstances, and far less collectible.

What shows up in this earnings cycle is the leading edge of that curve. The patients who lost coverage in early January, plus those retroactively losing coverage in April. The procedures quietly falling off outpatient schedules in the past thirty days. The early movement in self-pay ratios that financial teams are watching but not yet ready to characterize definitively.

The full weight of the policy decisions made last fall has not yet landed.

THE DIFFERENTIATOR NO ONE IS TALKING ABOUT YET

The industry has a reliable habit of describing structural change as temporary until the moment it becomes undeniable. Payer mix erosion will be called a transition. Site-neutral headwinds will be characterized as regulatory uncertainty awaiting resolution. Demand softness will be attributed to seasonality, consumer sentiment, or post-COVID normalization, anything that preserves the narrative of a return to baseline.

But the baseline no longer exists in the same form. And as that reality firms up over the coming quarters, the divergence between health systems will not be explained primarily by clinical footprint, geographic market, or even payer contract strength.

It will be explained by the capability of their revenue cycle organizations to see what is happening, and help organizations reposition.

The RCM function is entering a highly strategic period.  Measurement speed and structural flexibility are genuine competitive variables. Organizations that navigate this environment most effectively are those that can detect payer mix shifts at the encounter level in near real time, reprice their financial assistance and presumptive eligibility logic dynamically, and redirect operational capacity toward the patient segments and service lines where margin is still recoverable. That is not a workflow optimization problem. It is an AI enablement solution -- usually requiring a specialized approach -- and the gap between organizations that have made that investment and those that have not is about to become visible in ways that quarterly filings will make difficult to ignore.

Equally significant is where the volume is actually going. The patient populations moving into self-pay, charity care, and Medicaid are not marginal to health system strategy. They are becoming central to it, both as a financial management challenge and as a mission obligation. The systems that treated these segments as administrative afterthoughts, managing them with legacy workflows, manual screening processes, and underfunded teams are going to find that the policy environment has made that posture untenable. These are no longer edge cases. They are the growth surface of an increasingly uninsured and underinsured market. Skills which find alternative third party revenue sources and pursue TPL cash will be differentiating.

The policy chapter may be closed but the financial chapter is just opening. The RCM organizations that can read it in real time while adapting faster than the earnings cycle moves are the ones that will define what health system financial resilience actually looks like on the other side of this.

====================================================================

Larrian Martin is the Chief Information Officer at GoSB, a specialty RCM firm, and formerly EVP of Data & Insights at Envision Healthcare.

‍